SELLAS Life Sciences (SLS) Change in Receivables (2013 - 2022)

SELLAS Life Sciences (SLS) reported Change in Receivables of $1.0 million for Q1 2022, up 31.93% quarter-over-quarter from $758000.0 in Q2 2015.

SELLAS Life Sciences (SLS) Change in Receivables (2013 - 2022) Analysis & Trends

SELLAS Life Sciences (SLS) has 4 years of Change in Receivables data on file, last reported at $1.0 million in Q1 2022.

Change in Receivables for Q1 2022 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $979000.0 (down 38.16% YoY), and the FY2014 annual result was -$1.6 million, down 144.64% from the prior year.
Change in Receivables grew to $1.0 million in Q1 2022 per SLS's latest filing, from $758000.0 in the prior quarter.
Over five years, Change in Receivables peaked at $1.0 million in Q1 2022 and troughed at $1.0 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	22,529.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-39.80 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-4.08 Mn
10	SELLAS Life Sciences	1.39 Bn	1.39 Bn	-	-

Download Data